Abstract
Background: Activation of PI3 K signaling, mainly mediated via PI3Kδ,is a fundamental signaling cascade in lymphomas (Tarantelli et al, 2021). IOA-244 (IOA) is a highly selective and potent PI3Kδ inhibitor with atypical non-ATP competitive activity (Johnson et al, 2019) compared to FDA-approved PI3 K inhibitors idelalisib, copanlisib and duvelisib. IOA is in phase 1 as an immunomodulatory agent for patients with melanoma, mesothelioma, non-small cell lung cancer, myelofibrosis, and follicular and peripheral T cell lymphoma (TCL) as a single agent or in combination (NCT04328844).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
